San Francisco’s own lab-in-a-box rebels just secured $8M in Seed funding, oversubscribed, naturally, with Initialized Capital running point and Argon Ventures, Lowercarbon Capital doubling down on the bet they started in the $3M pre-seed. Now stack that with Julian Capital, Juniper, Future Labs Capital, LLC, 1517 Fund, Alumni Ventures, Angel Squad, sequel, Nucleus Capital, and Gaingels… and you start to understand the signal behind the noise. Because when serious capital flocks to your cap table like it’s the main stage at Red Rocks, you’re not just another bio-automation startup, you’re rewriting the tempo of the entire track.
Trilobio was founded in 2021 by Roya Amini-Naieni and Maximilian Schommer, two Forbes 30 Under 30 phenoms who didn’t just see the broken system in biology research, they lived it. Roya built labs from scratch, first for high schoolers, then at Harvey Mudd, where she ran headfirst into the clunky, overpriced, semi-useful lab robots that were supposed to “revolutionize” research. Instead, she did what real builders do, tore it down to the studs and started over.
The result? A full-stack automation platform built from the basement to the biosphere. The Trilobot forms the body, equipped with up to eight interchangeable tools, from pipettes to tube handlers, that self-calibrate and sync up like a modular robotic drumline. Trilobio OS handles the brains, a no-code interface that lets researchers design, tweak, and deploy protocols in minutes. The whole thing’s plug-and-play, you can unbox and get rolling in 30.
But let’s talk results. Trilobio’s pilots reported a 33% jump in throughput, 25% more data, and Triton Bio shaved 80 hours off onboarding. Deployed at places like The Leconte Group, Abalone Bio, and Triton Bio, this isn’t a “future of science” pitch, it’s a “we’re already there” beat. And when your platform makes reproducibility not just possible but inevitable, the research world listens.
This new round? It's fuel for scale. Expanding the Trilobio platform, leveling up the OS, and folding more precision-built tools into a single, autonomous system that puts million-dollar lab performance into the hands of everyday scientists.
Roya Amini-Naieni and Maximilian Schommer didn’t set out to automate labs, they set out to empower biologists. And now, with a war chest and a roster of real-deal backers, they’re doing exactly that.
Let’s connect and keep the momentum going across the tech ecosystem. Whether you’re a founder shaping the future, a leader driving change, a VC backing bold ideas, or an investor spotting the next big thing—together, we’re pushing boundaries. Proud to be building the future with you.
Let’s connect on LinkedIn and Twitter (X), and keep the conversation going.